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Purpose: The aim of this study is to evaluate the feasibility of the procedure in day-hospital and discuss
prognostic factors, efﬁcacy and complications of percutaneous radiofrequency ablation in the treatment
of renal cell carcinoma.
Materials and methods: Between January 2003 and August 2008, 26 patients (mean age 79, range 70–
87 years, 15 men and 11 women) affected by 27 kidney tumoral lesions, 25 RCC and two renal oncoci-
tome (one patient was affected by two RCC), undergo 29 treatments of RFA (three patients underwent
two treatments due to residual tumor at the CT performed 1 month after the ﬁrst treatment). Three out
of 26 patients had only one kidney due to progressed nephrectomy because of RCC; three/26 patients
were carriers of oncological comorbidity while four/26 patients were carriers of medical comorbidity.
The remaining 16/26 patients refused the surgical option. The lesions had a diameter between 1 and 4 cm
(average diameter 2.4 cm). Seventeen of the 27 lesions were exophytic, ﬁve/27 parenchymal, three/27
was central while two/27 was mixed. All the lesions had been characterized either by CT or MRI. On the
basis of the same investigation the feasibility of the radiofrequency procedure was veriﬁed. For all the
procedures the RF type 3000 radiofrequency generator system was used together with the LeVeen
ago-electrode. Twenty-one lesions out of 27 were treated under ultrasound guidance while six/27 lesions
under the CT guide. After the procedure a US control was performed to exclude early complications and
the same day the patients were discharged from hospital: the procedure was performed in day-hospital.
Results: The technical success of the procedure was obtained in all cases (100%). After the procedure, 18
patients, without complications and comorbidity, were discharged from hospital the same day, seven
patients with comorbidity were kept under observation for one night while one patient was hospitalized.
The primary success of the treatment, rated with CT or MRI after 1 month, was obtained in 25/27 of the
cases. In two/27 lesion, an incomplete ablation was obtained; for this reason these patients underwent
a second treatment and after 6 month of a regular follow-up, no more neoplastic tissue was identiﬁed.
During the follow-up there were no signs of disease in any patients. No major peri-procedural compli-
cations were recorded; only one patient had to be assisted for the appearance of a peri renal liquid
(urinoma) and a thin pneumothorax layer that resolved completely in few days after the procedure.
Conclusions: Preliminary results with RFA of RCC are promising. Radiofrequency thermal ablation could
prove to be a useful treatment for patients who are unsuitable for surgery; in this study we demonstrate
the feasibility of the treatment in day-hospital for selected patients.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.al Radiology, Department of
ly. Tel.: þ39 033 227 8770;
ciates Ltd. Published by Elsevier Lt1. Introduction
Renal cell carcinoma (RCC) is the most common primary
parenchymal malignancy of the kidney and accounts for 2% of all
new cancers annually in the United States.1d. All rights reserved.
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because of the increasing use of imaging techniques.2,3 In almost
two thirds of cases, RCC currently diagnosed are incidental ﬁndings
in asymptomatic patients.2
The traditional standard treatment for localized RCC is partial or
radical nephrectomy, but this method is not ideal for treating all
tumors because some patients are unable or unwilling to undergo
surgery or would have limited or no functional renal tissue
remaining after standard therapy. One possible alternative treat-
ment for such patients is radiofrequency ablation (RFA).
We reviewed our experience with 26 patients who underwent
RFA for renal neoplasm to evaluate prognostic factors, efﬁcacy and
complications of treatment.Fig. 1. LeVeen ago-electrode.2. Materials and methods
Between January 2003 and August 2008, 26 patients (mean age
79, range 70–87 years, 15 men and 11 women) affected by 27
kidney tumoral lesions, 25 RCC and two renal oncocitome (one
patient was affected by two RCC), undergo 29 treatments of RFA
(two patients underwent two treatments due to residual tumor at
the CT performed 1 month after the ﬁrst treatment).
All patients were unsuitable to the surgical treatment.
Three out of 26 patients had only one kidney due to progressed
nephrectomy because of RCC; three/26 patients were carriers of
oncological comorbidity (pulmonary carcinoma, gastric carcinoma)
while four/26 patients were carriers of medical comorbidity (aortic
aneurysm in two cases and chronic renal insufﬁciency in the other
two patients). The remaining 16/26 patients refused the surgical
option.
The lesions had a diameter between 1 and 4 cm (average
diameter 2.4 cm). In one patient, two lesions were treated in one
single session.
In accordance with the classiﬁcation proposed by Gervais,4,5 17/
27 lesions were found to be exophytic, ﬁve/27 parenchymal, three/
27 central while two/27 was mixed.
Seventeen lesions were situated on the left kidney, and 10 on
the right one.
The lesions had been characterized by CT (LightSpeedPlus / GE
/ Milwaukee / USA or Aquilion 64 / Toshiba / Tokyo /Japan) in 25/26
patients while in one/26 patients, was performed MRI (Eclipse /
Picker-Marconi /1.5 T). On the basis of the same investigation the
feasibility of the radiofrequency procedure was veriﬁed. For all
tumors with a diameter 3 cm was performed renal biopsy by
means of an 21 Gauge needle (Biomodl); in two cases was per-
formed renal biopsy by means of an 18 Gauge needle, which
conﬁrmed the diagnosis of renal oncocitome.
For the other patients, no biopsy was carried out in consider-
ation of the risks connected with the puncture (bleeding, seeding,
artero/venous ﬁstulas).
In seven cases was utilized contrast enhancement to visualize
the lesions (SONOVUE).
Twenty-one lesions out of 27 were treated under ultrasound
(US) guidance (Technos MPX, Esaote, Genova, Italy; iU22 Philips,
Eindhoven, The Netherlands), 5/27 lesions were treated under CT
guidance (Aquilion 64 / Toshiba / Tokyo/ Japan).
For all devices, the skin at the site of the planned needle
puncture was anaesthetized with 1% lidocaine. The patients were
treated under deep sedation according to the principles of ‘‘moni-
tored anaesthesia care’’ receiving propofol (50–120 mg), alfentanyl
(0.5–1 mg) and mydazolam (1–3 mg). All patients received oxygen
during the procedures. Continuous monitoring of heart rate, elec-
trocardiographic tracing, oxygen saturation, and respiratory rate
were obtained, and blood pressure was determined every 4 min.For all procedures the RF type 3000 radiofrequency generator
system was used together with the LeVeen ago-electrode (Fig. 1).
In one case the LeVeen 4 cm needle was used, in 10 cases the
LeVeen 3.5 cm needle was used, and in 12 cases was the LeVeen
3 cm, and in four cases the LeVeen 2 cm needle was used.
At the end of the procedure a US control was performed to
exclude major complications [1 – require therapy or minor hospi-
talization (<48 h); 2 – requiremajor therapy, unplanned increase in
the level of care, prolonged hospitalization (>48 h); 3 – permanent
adverse sequelae; and 4 – death] and minor complications [1 – no
therapy, no consequence; and 2 – nominal therapy, no conse-
quence; includes overnight admission for observation only].6 The
patients with major complications were kept under observation in
hospital for at least one night; the others patients without
complications and clinical or oncological comorbidity were dis-
charged from hospital the same day of the procedure.
We deﬁned the technical success as the correct positioning of
the needle inside the lesion.
The patients were then taken through a follow-up visit by
means of CT or MRI at 1, 3, 6 and 12 month intervals after the
procedure and then once per year. Primary success was deﬁned as
no enhancement or enlargement of the treated lesions, and this
ﬁnding is consistent with local control; any focal enhancement in
the ablated lesion was be considered indicative of residual or
recurrent tumor. The patients with clinical and oncological
comorbidity (6) were kept under observation in hospital. During
the follow -up period major complications and minor complica-
tions are scheduled.
3. Results
The technical success of the procedure was obtained in all cases
(100%).
The primary success of the treatment, assessed when CT or MRI
completed after 1 month, was obtained in 25/27 of the cases in
which no enhancement or enlargement of the treated lesion was
observed (Figs. 2 and 3). In two/27 lesions, an incomplete ablation
was obtained; for this reason this patient underwent a second
treatment and after 6 months of a regular follow-up, no more
neoplastic tissue was identiﬁed.
No major peri-procedural complications were recorded; only
one patient had to be assisted for the appearance of a perirenal ﬂuid
collection (urinoma) and a thin pneumothorax (PNX). Subsequent
examinations (US of the abdomen and X-ray ﬁlm of the chest in two
Fig. 2. a: Enhanced CT scan shows the RF multitines electrode in place within the
upper pole mass. b: Immediate postablation contrast enhanced CT scan shows
stranding and fascial thickening (arrow). Arrowhead indicates the ablation zone.
Fig. 3. a: Pre-ablation contrast enhanced CT scan shows a small exophytic tumor
(arrow). b. Contrast-enhanced CT scan obtained 4 weeks after RFA demonstrates an
area (arrow) of non-enhancing soft-tissue attenuation (ablation zone).
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within 3 days of the procedure and the complete disappearance of
the of the PNX 12 h after the treatment.
Eighteen of 26 patients were discharged from hospital after US
control the same day of the procedure while the others with
oncological or clinical comorbidity were kept under observation for
at least one night.
None of the patients has shown a renal failure after the
procedure.
During the follow-up there were no signs of the recurrence in
any of the patients. All the patients underwent CT or MRI controls
for a period of 2 years in one case, 18 months in two cases, 1 year in
four cases, of 9 months in two cases, of 6 months in six cases, of
3 months in two cases, of 2 months in one and of 1 month in eight
cases. The average value of follow-up is 7 months.4. Discussion
From the ﬁrst indication of renal neoplasm treatment by RFA,
10 years have passed and the subsequent reports have highlighted
a progressive numerical increase in patients undergoing such a cure
with satisfactory results.7 In our Institution we performed more
than 500 RFA. The treatment is safe and minimally invasive, than in
patients without clinical or oncological comorbidity and post-treatment complications, we kept them in observation only for
1 day: the procedure was performed in day-hospital.
Potential candidates for thermal ablation fall into three general
categories: 1 – patients who are poor operative candidates as
a result of inadequate renal function and/or comorbid disease; 2 –
patients at high risk for the development of additional RCC in the
future (patients with von Hippel–Lindau syndrome, hereditary
papillary cell carcinoma, or hereditary clear-cell carcinoma) in
whom the least invasive nephron-sparing approach is desirable;
and 3 – patients refusing surgical option.9
From literature it can be seen how the most important predic-
tive factors of the success of the treatment are the localization and
size of the neoplasm.4–11
The exophytic lesions are the ones with the best results due to
the so-called ‘‘oven effect’’ determined by the perirenal fat which
represents an optimal isolating material reducing the dispersion of
thermal energy. The issue is the opposite if one considers the
parenchymal or central lesions, since the renal parenchymal is
richly vascularized and the renal pelvis is often in contact with the
lesion to be treated. In both cases there is a marked thermal
dispersion due to the ematic ﬂow and for the urine contained in the
calicial-pelvis.4,5
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regular follow-up, were completely ablated after the ﬁrst treatment.
There were no signs of residual disease in the central lesions,
which differs from that written in literature, but probably the cause
in our series is due to a not so large number of patients.
In literature it is reviewed that another predictive factor for the
success is represented by the size of the lesions.12,13
The lesions treated in the personal series showed a diameter of
2.4 cm (range 1 –4 cm) mainly in agreement with the previous
experience, in which the average diameter was 2.2 cm (range
0.6–8.9 cm).7,14–48
It is well known that an increase in the diameter of the lesion
corresponds to a signiﬁcant reduction in the response to treatment.
The larger tumors require multiple overlapping ablations and in
same cases return visits for additional ablation session.4
Our data agrees with previous experiences which are exclu-
sively considering those studies with an average follow-up of at
least 36 months in which about 15 patients were treated;9–11,16–21
the procedure has proved to be resolute (no disease) in 387/420
lesions <3 cm and 69/92 lesions between 3 and 9 cm.
Nevertheless the size of the lesion does not present an absolute
limit in RFA treatment of renal neoplasm in relation to the avail-
ability of different strategies such as the simultaneous positioning
of several needles, overlapping of several treatments, the injection
of saline solutions, application of radiofrequency with pulsed
technology, arterious adjuvante and occlusion pharmacological
treatments.13,30
In our experience, the lesions greater than 3 cm (six lesions) were
efﬁcacy treated after two overlapping treatments. This evidence
substantially coincides in what many authors had previously
underlined; tumors larger than 3 cm can be treated successfully but
sometimes required multiple RFA and sessions.9–11,14,16,31–33
The US guide was used in 21/27 cases, while for the remaining
six the CT guide was used while data in literature showed CT
preference for the Anglo–Saxon countries and US guide preference
in other experiences.7,10–16,17–48Table 1
Personal experience.
N/age/sex N lesions Diameter (cm) Position Side Treatment G
1/73/M 1 2.6 Parenchymal Left 1 T
2/82/M 1 2 Central Right 1 T
3/81/F 1 3 Parenchymal Left 1 U
4/85/F 1 4 Mixed Right 2 U
5/81/F 1 1 Exophytic Left 1 U
6/80/F 1 4 Exophytic Left 1 T
7/70/M 1 1.3 Exophytic Left 2 U
8/70/M 1 3 Exophytic Left 1 U
9/80/F 1 1.8 Exophytic Left 1 U
10/81/F 1 3.6 Exophytic Left 1 U
11/79/F 1 4 Exophytic Left 1 U
12/83/M 1 2.7 Exophytic Left 1 U
13/78/M 1 1.5 Exophytic Left 1 U
14/81/M 1 3 Exophytic Left 1 U
15/81/M 1 1.2 Exophytic Right 1 U
16/80/M 2 3.2 Exophytic Left– 1 U
2.4 Central Right
17/85/M 1 1 Exophytic Right 1 U
18/81/M 1 3 Exophytic Right 1 U
19/84/F 1 4 Exophytic Left 1 U
20/70/F 1 1 Parenchymal Right 1 U
21/81/F 1 1.3 Parenchymal Left 1 U
22/71/M 1 2.2 Exophytic Right 1 U
23/74/M 1 1.5 Exophytic Left 1 U
24/85/F 1 3 Parenchymal Right 1 U
25/72/M 1 2.5 Central Right 1 T
26/87/M 1 2 Mixed Left 1 TFrom a comparisonwith literature, taking into consideration the
greater cases (about 15 patients treated) with follow-up greater
than 7 months (average of 12.6 months, range 7 months –
2.3 years),10–12,17–21,28 it can be seen that our study is weighted by
an higher percentage of success rate (100 against 96%). The reasons
for this result are to be found in two factors: size of tumor and
localization. In the personal experience six lesions had a dimension
larger than 3 cm and most of the lesions treated in our Institution
were exophytic (17/27) Table 1.
The procedure, is characterized by a low percentage of compli-
cations as can be seen from the literature:10,12–20,30–38 in our expe-
rience no major peri-procedural complications occurred. In only one
patient we observed a thin PNX and a perirenal urinoma that did not
bring about alterations of the ematochemical parameters.
The perirenal urinoma and PNX represent a recognized
complications as reported in the Classiﬁcation system used by The
Society of International Radiology.8
Subsequent controls performed with US of the abdomen and X-
ray ﬁlm of the chest in two projections, showed the complete
resolution of the perirenal urinoma after 3 days after the procedure
and complete re-absorption of the PNX after 12 h.10,12–16,18–20,30–38
On the basis of our experience, the procedure can be performed
in day -hospital in patients without comorbidity and complications.
5. Conclusions
Radiofrequency thermal ablation could prove to be a useful
treatment for patients who are unsuitable for surgery; in this study
we demonstrate the feasibility of the treatment in day-hospital for
selected patients.
In general, RCC smaller than 3 cm can in diameter are ideal for
ablation, with near-perfect success rates on post procedural
imaging; most tumors smaller than 3 cm often can be treated
successfully in a single session. Tumors between 3 and 5 cm in
diameter can also be treated successfully with conﬁdence, but
multiple ablations and sessions may be required; the presence ofuidance Needle Primary success Follow-up
C LeVeen 3 cm Complete ablation 12 months: complete ablation
C LeVeen 3 cm Complete ablation 12 months complete ablation
S LeVeen 3 cm Complete ablation 9 months: complete ablation
S LeVeen 4 cm Residual lesion 6 months: complete ablation
S LeVeen 3 cm Complete ablation 6 months: complete ablation
C LeVeen 3 cm Complete ablation 3 months: complete ablation
S LeVeen 3 cm Complete ablation 9 months: complete ablation
S LeVeen 2 cm Complete ablation 12 months: complete ablation
S LeVeen 3.5 cm Complete ablation 2 years: complete ablation
S LeVeen 3 cm Complete ablation 6 months: complete ablation
S LeVeen 3 cm Complete ablation 6 months: complete ablation
S LeVeen 2 cm Complete ablation 18 months: complete ablation
S LeVeen 3.5 cm Complete ablation 18 months: complete ablation
S LeVeen 3.5 cm Complete ablation 1 month: complete ablation
S LeVeen 3.5 cm Complete ablation 1 month: complete ablation
S LeVeen 3.5 cm Complete ablation 1 month: complete ablation
S LeVeen 2 cm Complete ablation 1 month: complete ablation
S LeVeen 3.5 cm Complete ablation 1 month: complete ablation
S LeVeen 3.5 cm Complete ablation 6 months: complete ablation
S LeVeen 2 cm Complete ablation 2 months: complete ablation
S LeVeen 3.5 cm Complete ablation 3 months: complete ablation
S LeVeen 3.5 cm Complete ablation 1 month: complete ablation
S LeVeen 3 cm Complete ablation 12 months: complete ablation
S LeVeen 3 cm Complete ablation 1 month: complete ablation
C LeVeen 3 cm Complete ablation 1 month: complete ablation
C LeVeen 3 cm Complete ablation 6 months: complete ablation
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there does not appear to be a high risk of systemic spread from foci
of residual tumor.
The location of the tumor (exophytic, parenchymal, mixed or
central) also inﬂuences ablation results. Parenchymal, mixed or
central tumor may be more difﬁcult to be treated: the presence of
a central component in a RCC larger than 3 cm is reported to be
a signiﬁcant predictor of failure.4,7
Additional long term data regarding local and systemic relapse
and survival are needed before the oncology efﬁcacy of this tech-
nique can be veriﬁed for therapy of RCCs.
Current ﬁndings suggest that RFA for RCC is an acceptable
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